StockData
XTL Biopharmaceuticals Ltd logo

XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30
$1.62+0.08 (+5.19%)

Close on Nov 17, 2026Market cap $15.33MP/E –Yield –

XTL Biopharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

XTL Biopharmaceuticals's pe ratio was 8.9× on Feb 28, 2020.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Feb 28, 20208.9×−0.2
2019Dec 31, 20199.1×–

More XTL Biopharmaceuticals figures

See a number that looks wrong?